A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Status:
Completed

Trial end date:
2018-06-08

Target enrollment:

Participant gender:

This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.

Phase 3

Shire

Hormones